• Publications
  • Influence
Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease.
BACKGROUND In January 2005, a quadrivalent (serogroups A, C , Y, and W-135) meningococcal conjugate vaccine was licensed for use in adolescents. This report describes the epidemiologic features ofExpand
  • 246
  • 17
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2015.
The Advisory Committee on Immunization Practices (ACIP) recommends that adolescents aged 11-12 years routinely receive vaccines to prevent diseases, including human papillomavirus (HPV)-associatedExpand
  • 311
  • 14
Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
CDC, our planners, and our content experts wish to disclose that they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercialExpand
  • 84
  • 14
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2014
Routine immunization is recommended for adolescents aged 11-12 years by the Advisory Committee on Immunization Practices (ACIP) for protection against diseases including pertussis, meningococcalExpand
  • 581
  • 12
Predictors of PFOA Levels in a Community Surrounding a Chemical Plant
Background Perfluorooctanoic acid (PFOA) is considered a probable human carcinogen by the U.S. Environmental Protection Agency. It does not exist in nature but has been used widely since World WarExpand
  • 106
  • 12
Current epidemiology and trends in invasive Haemophilus influenzae disease--United States, 1989-2008.
BACKGROUND With the introduction of Haemophilus influenzae serotype b (Hib) conjugate vaccines, there has been a dramatic reduction of Hib disease in young children and the epidemiological trends ofExpand
  • 118
  • 10
Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015.
At its June 2015 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended that adolescents and young adults aged 16–23 years may be vaccinated with a serogroup B meningococcalExpand
  • 137
  • 9
A cross-sectional analysis of type II diabetes in a community with exposure to perfluorooctanoic acid (PFOA).
BACKGROUND Increased diabetes mortality has been reported in workers exposed to perfluorooctanoic acid (PFOA). We analyzed the relationships among serum PFOA, type II diabetes, and fasting glucose inExpand
  • 62
  • 6
Early Estimate of the Effectiveness of Quadrivalent Meningococcal Conjugate Vaccine
Background: In January 2005, a quadrivalent meningococcal conjugate vaccine (MenACWYD) was licensed for use in the United States. The Advisory Committee on Immunization Practices recommends MenACWYDExpand
  • 53
  • 5
National and State Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2012
At ages 11 through 12 years, the Advisory Committee on Immunization Practices (ACIP) recommends that preteens receive 1 dose of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine, 1 dose ofExpand
  • 305
  • 4